Navigation Links
Smallest full support heart assist device on trial at Northwestern Memorial
Date:4/27/2009

CHICAGO - Northwestern Memorial Hospital's Bluhm Cardiovascular Institute is the first center in Chicago and among the first in the country to implant a new experimental left ventricular assist device (LVAD) into subjects with advanced heart failure, a condition where the heart cannot pump enough blood to the body's organs. The HeartWare Ventricular Assist System (HeartWare System) features the HVAD Pump, the smallest LVAD to provide full cardiac support currently under investigation in the United States. The HeartWare System is intended as a bridge to heart transplantation. Northwestern Memorial surgeons have implanted four subjects with the device, and are the first in the country to transplant a subject as part of this trial.

Individuals with advanced heart failure experience symptoms such as swelling, fatigue, shortness of breath and are not able to exert themselves. Medications are often successful for managing symptoms in the earlier stages of heart failure, but for patients in the late-stages heart transplantation is considered the best treatment option. However, with just over 2,000 donor hearts becoming available each year, the wait for a transplant can be long. The smaller model is being studied as a less cumbersome LVAD procedure in subjects with advanced-stage heart failure who need support to survive until a donor heart becomes available. In subsequent trials the HVAD Pump will be trialed in subjects that are not transplant candidates.

Edwin McGee Jr., MD, the principal investigator of the trial, cardiac surgeon and the surgical director of Heart Transplantation and Mechanical Assistance at the Bluhm Cardiovascular Institute, lead the team that implanted the four subjects. The national clinical trial hopes to enroll up to 150 subjects. Twenty-two subjects have been enrolled in the U.S to date.

"The small size and unique configuration of this particular model allows us to place it adjacent to the ventricle itself, as opposed to implanting the device in the abdominal wall," commented Dr. McGee. "This is a major step forward, as it is intended to reduce the potential risks associated with a more extensive surgery such as bleeding and infections. We are also able to cast a wider net of potential subjects and can include more women in the trials since the device is significantly smaller than previous models."

The device is a tiny centrifugal blood pump, with a levitating impeller that spins to continuously move blood from the heart to the rest of the body. A driveline cable attaches to the pump and connects to a portable controller, powered by a pair of battery packs, worn by the subject allowing for mobility.

According to the American Heart Association, 4.9 million patients in the United States suffer from heart failure, with an additional 550,000 diagnosed each year. The National Institutes of Health estimates that in the US, approximately 100,000 patients per year could benefit from an LVAD.

"Heart failure is a growing epidemic in this country and we hope that this trial will lead to better outcomes and fewer complications for patients with severe heart failure," said Dr. McGee. This LVAD is the next step in the evolution of heart assist devices, which, in the future, could result in a fully-implantable model.


'/>"/>

Contact: Amy Dobrozsi
adobrozs@nmh.org
312-926-5900
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. VIDEO from Medialink and Abiomed: Worlds Smallest Heart Pump Receives 510(K) Clearance from FDA
2. LightAir Cleans the Air From the Smallest and Most Dangerous Particles Without Generating Ozone
3. Smallest Air Pollution Particles Hurt Heart Most
4. VIDEO from Medialink and Siemens: Worlds Smallest Ultrasound Package Launches in the U.S.
5. Good Imaging Now Comes in the Worlds Smallest Ultrasound Package
6. Medicare Offers Smallest Rise in Premiums in 6 Years
7. Thermal Angel Supports Infection Control During the Golden Hour
8. Teamsters, Area Unions Rally in Support of Rural/Metro Workers
9. Cardinal Rigali Praises House Re-Introduction of Pregnant Women Support Act, Urges Co-Sponsorship
10. New Evidence Supports Efficacy and Value of Smith & Nephew NPWT Products
11. Wounded Warrior Project (WWP) Announces Support for Soldier Ride from Boston Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... DC (PRWEB) , ... March 28, 2017 , ... WHO: ... Dr. Toni Bark , WHAT: , Medical doctors and PhD scientists will speak to ... written to President Trump in support of an independent vaccine safety commission. , ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... instruments are critical to ensuring high-quality results and maintaining GMP and USP compliance. ... Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... Vilnius, Lithuania (PRWEB) , ... March 28, 2017 ... ... identification technologies, today announced the release of two biometric time and attendance tracking ... Bio Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition ...
(Date:3/28/2017)... ... 2017 , ... In its ongoing effort to educate consumers ... and published an informational resource that addresses frequently asked questions. , “ ... site’s team of third party administrator (TPA) contributors regularly receives as employers, benefit ...
(Date:3/28/2017)... ... , ... A minimally invasive porcelain veneer is increasing in ... of Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive ... laboratories and technicians that create these veneers. , According to National Board ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Elysium Health joins major pharmaceutical companies to ... Cambridge academic scientists through ... Institute today announces Elysium Health as a partner to the ... collaborative projects with academic researchers in Cambridge ... major research investment outside the U.S. for the ...
(Date:3/27/2017)... Summary This report provides all the information ... interests and activities since 2010. Description The Partnering Deals ... the partnering activity of one of the world,s leading life ... upon purchase to ensure inclusion of the most up to ... be delivered in PDF format within 1 working day of ...
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
Breaking Medicine Technology: